Work

Figure 2 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy

Year: 2026

Type: other

Abstract: Schematic illustration of DualADC conjugation strategies and HPLC characterization. A, mAb-DM1/IMQ: conjugation of DM1 to the mAb via a lysine-based strategy, followed by conjugation of IMQ to the TCEP-reduced mAb-DM1 ADC via a cysteine-based strategy. B, HPLC characterization confirming the conjugation of mAb-DM1/IMQ. C, mAb-DXd/IMQ: conjugation of DXd to the TCEP-reduced mAb via a cysteine-based strategy, followed by conjugation of IMQ via a lysine-based strategy. D, HPLC characterization confirming the conjugation of mAb-DXd/IMQ. E, mAb-MMAF/IMQ: conjugation of MMAF to the TCEP-reduced mAb via a cysteine-based strategy, followed by conjugation of IMQ to the mAb-MMAF ADC via a lysine-based strategy. F, HPLC characterization confirming the conjugation of mAb-MMAF/IMQ.

DOI: 10.1158/2767-9764.32702391

Authors: Zhuoxin Zhou, Davis Ballard, Jiashuai Zhang, Zhantao Du, Natsorn Watcharadulyarat, Tanvi Varadkar, Srijita Chowdhury, Sathvik R. Kambam, Phoebe Hu, Selena Khanal, Lufang Zhou, Xiaoguang Liu

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W7165009237

Cites:

Cited by:

Related to: 10